Microbiological study of ventilator-associated pneumonia (VAP) after implantation of pneumonia program zero (NZ)
- 231 Downloads
KeywordsInflammatory Response Severe Sepsis Levofloxacin Nosocomial Infection Amikacin
The National Survey of Nosocomial Infection Surveillance (ENVIN) is a computerized record of the incidence of nosocomial infection in ICU in Spain. In our hospital, we have drafted rules for the maintenance of the airway in mechanically ventilated patients following general recommendations.
Describe the clinical diagnosis and microbiology of VAP after the implementation of the NZ program.
18 ICU beds. Data from ENVIN 01.04.11 / 01.04.15 (clinical diagnosis, microorganisms isolated and antibiotic resistance, inflammatory response ).
NZ: Educational campaign (presencial and by means of internet) to professionals of our unit and anesthesia-resuscitation unit (112 professionals). Were instituted mandatory measures for the prevention of VAP.
01.04.11/01.04.12- 15 VAP.
- Clinical diagnosis:
support clinical radiological+new infiltrate 80%.
Extension of previous infiltrate + clinical worsening (2nd pneumonia)20%
A. baumanii 44.44%: resistance: amikacin, ampicilin, imipenem, tobramicin
P. aeuroginosa 22.22%: resistance: amikacin, ceftacidim, ciprofloxacin,
colistin, imipenem, levofloxacin, meropenem, piperacilina-tazobactam (P-T)
- Inflammatory response: sepsis 33.33%, severe sepsis 33.33%.
support clinical radiological+new infiltrate 66.67%
extension of previous infiltrate + clinical worsening (2nd pneumonia) 16.67%,
S. Aureus 22 .22%: no resistance
S. Maltophilla 22.22% no resistance
Without diagnostic 16.67%
- Inflammatory response: sepsis 50%, severe sepsis 33.33%, shock 16.67%
01.04.13/01.04.14- 10 VAP
support clinical radiological+new infiltrate 60%
extension of previous infiltrate + clinical worsening (2nd pneumonia) 30%,
S. Aureus 25%
E. Coli 16.67%: resistance: ciprofloxacin, amox-clav.
H. Influnzae 8.33%
P. aeuroginosa 8.33%: resistance :cefepime, ceftacidime, imipenem,
- Inflammatory response: sepsis 50%, severe sepsis 30%, shock 20%.
support clinical radiological+new infiltrate 68.57%
extension of previous infiltrate + clinical worsening (2nd pneumonia) 22.86%
A. baumanii 18.6% . Resistance: amikacin
P. aeuroginosa 16.28% . Resistance: amikacin, cefepime
S. aureus 13.95%: no resistance
- Inflammatory response: sepsis 33.33%, severe sepsis 66.67%
Most of the diagnoses are made by the patient's clinical and x-ray. Each year vary germs being the most frequent S. aureus and P. aeruginosa. Usually, the most common inflammatory response is sepsis. The P. aeruginosa is the germ which has more resistance.
UCI S. Cecilio
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.